Cell-mediated Cytotoxicity in Glioma-bearing Patients: Differential Responses of Peripheral Blood Mononuclear Cells to Stimulation with Interleukin-2 and Microbial Antigen

Overview

Journal J Neurooncol

Publisher Springer

Date 1988 Dec 1

PMID 3146618

Citations 3

Authors

C Ausiello

A Maleci

G C Spagnoli

G Antonelli

A Cassone

Affiliations

Soon will be listed here.

Abstract

Peripheral blood mononuclear cells (PBMC) of malignant glioma-bearing patients were stimulated in vitro with Interleukin-2 (IL-2) or a glucomannan-protein antigen of Candida albicans (GMP) then assayed for proliferation, production of IFN-gamma, and generation of cytotoxic effectors against either K562 tumor cell line or freshly-cultured allogenic glioma cells. PBMC of healthy, age and sex-matched subjects were the controls. PBMC of glioma-bearing patients did not differ, as a whole, from PBMC of healthy donors in IL-2 or GMP-induced proliferation. However, they showed a lesser ability to produce IFN as well as a substantial inability to generate cytotoxic effectors following GMP stimulation. PBMC of glioma patients were fully responsive to IL-2 in cytotoxicity generation, as were the PBMC from normal subjects. The results suggest that glioma patients may have a defective antigen-mediated activation of natural cytotoxic effectors. This hyporesponsiveness is not accompanied by depressed lymphoproliferation and does not apparently involve a reduced response to IL-2.

Citing Articles

Microbial immunomodulators: mannoprotein constituents ofCandida albicans with immunomodulatory activity in lymphocyte cultures of normal, glioma-bearing and HIV-infected subjects.

Cassone A, Quinti I, Ausiello C, Palma C, Gomez M, Maleci A Cytotechnology. 2012; 5(Suppl 1):7-10.

PMID: 22358941 DOI: 10.1007/BF00736795.

Growth inhibition of Candida albicans by interleukin-2-activated splenocytes.

Beno D, Mathews H Infect Immun. 1992; 60(3):853-63.

PMID: 1541559 PMC: 257565. DOI: 10.1128/iai.60.3.853-863.1992.

The cytotoxic action of lymphokine activated killer cells upon the human glioma cell line U251 is stimulated by bispecific monoclonal antibody (MoAb) constructs.

Obukhov S, Gennie M, Tutt A, Kemshead J, Coakham H, Beverely P J Neurooncol. 1992; 13(3):203-10.

PMID: 1517796 DOI: 10.1007/BF00172471.

References

Ullen H, Blom U, Blomgren H . Natural killer activity of blood lymphocytes in patients with primary intracranial tumors. Correlation to histological tumor type and anatomical site. Eur J Cancer Clin Oncol. 1986; 22(10):1239-45. DOI: 10.1016/0277-5379(86)90326-3. View

Rosenberg S . Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985; 75(4):595-603. View

Ausiello C, Sorrentino V, Ruggiero V, Rossi G . Action of lysosomotropic amines on spontaneous and interferon enhanced NK and CTL cytolysis. Immunol Lett. 1984; 8(1):11-5. DOI: 10.1016/0165-2478(84)90097-x. View

MAHALEY Jr M, Brooks W, Roszman T, Bigner D, Dudka L, Richardson S . Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg. 1977; 46(4):467-76. DOI: 10.3171/jns.1977.46.4.0467. View

Brooks W, NETSKY M, Normansell D, Horwitz D . Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med. 1972; 136(6):1631-47. PMC: 2139329. DOI: 10.1084/jem.136.6.1631. View

STANTON G, Langford M, Dianzani F . Virus yield-reduction assay for interferon by titration of Sindbis virus hemagglutinin. Methods Enzymol. 1981; 78(Pt A):351-7. DOI: 10.1016/0076-6879(81)78141-2. View

Tartof D, Curran J, Levitt D, Loken M . The skin test antigen stimulated killer (STAK) cell mediating NK like CMC is OKM1 positive and OKT3 negative. Clin Exp Immunol. 1983; 54(2):561-6. PMC: 1535880. View

Tartof D, Check I, Matutis A, Hunter R, Fitch F . Studies on stimulation of cell-mediated cytotoxicity by skin test antigens. I. Candida antigen stimulation of cell-mediated cytotoxicity in vitro correlated with the skin test response to candida antigen in vivo. J Immunol. 1980; 125(6):2790-6. View

Hahn B, Macdermott R, Jacobs S, Pletscher L, Beale M . Immunosuppressive effects of low doses of glucocorticoids: effects on autologous and allogeneic mixed leukocyte reactions. J Immunol. 1980; 124(6):2812-7. View

10.

Dianzani F, Monahan T, Scupham A, Zucca M . Enzymatic induction of interferon production by galactose oxidase treatment of human lymphoid cells. Infect Immun. 1979; 26(3):879-82. PMC: 414702. DOI: 10.1128/iai.26.3.879-882.1979. View

11.

Fontana A, Hengartner H, Tribolet N, Weber E . Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol. 1984; 132(4):1837-44. View

12.

Blomgren H, Blom U, Ulen H . Relation between the site of primary intracranial tumors and mitogenic responses of blood lymphocytes. Cancer Immunol Immunother. 1986; 21(1):31-8. PMC: 11038742. DOI: 10.1007/BF00199374. View

13.

Jacobs S, Wilson D, KORNBLITH P, Grimm E . Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg. 1986; 64(5):743-9. DOI: 10.3171/jns.1986.64.5.0743. View

14.

Roszman T, Brooks W, ELLIOTT L . Immunobiology of primary intracranial tumors. VI. Suppressor cell function and lectin-binding lymphocyte subpopulations in patients with cerebral tumors. Cancer. 1982; 50(7):1273-9. DOI: 10.1002/1097-0142(19821001)50:7<1273::aid-cncr2820500709>3.0.co;2-5. View

15.

Jacobs S, Wilson D, KORNBLITH P, Grimm E . In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg. 1986; 64(1):114-7. DOI: 10.3171/jns.1986.64.1.0114. View

16.

Ausiello C, Spagnoli G, Antonelli G, Malavasi F, Dianzani F, Casciani C . Generation and characterization of cytotoxic activity against tumor cell lines in human peripheral blood mononuclear cells stimulated "in vitro" by a glucomannan-protein preparation of Candida albicans. J Biol Regul Homeost Agents. 1987; 1(2):59-68. View

17.

Dianzani F, Santiano M, Ramenghi U, Capobianchi M, Antonelli G . Membrane events leading to interferon-gamma induction by antigens. Proc Soc Exp Biol Med. 1985; 178(1):139-42. DOI: 10.3181/00379727-178-41995. View

18.

SCHWYZER M, Fontana A . Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells. J Immunol. 1985; 134(2):1003-9. View

19.

Lauro G, Di Lorenzo N, Grossi M, Maleci A, GUIDETTI B . Prostaglandin E2 as an immunomodulating factor released in vitro by human glioma cells. Acta Neuropathol. 1986; 69(3-4):278-82. DOI: 10.1007/BF00688305. View

20.

Ommaya A . Immunotherapy of gliomas: a review. Adv Neurol. 1976; 15:337-59. View